Edition:
United Kingdom

Mitsubishi Chemical Holdings Corp (4188.T)

4188.T on Tokyo Stock Exchange

852JPY
13 Dec 2018
Change (% chg)

¥3 (+0.38%)
Prev Close
¥849
Open
¥859
Day's High
¥861
Day's Low
¥849
Volume
5,919,900
Avg. Vol
5,789,346
52-wk High
¥1,320
52-wk Low
¥829

Latest Key Developments (Source: Significant Developments)

Mitsubishi Chemical Holdings Corp - Announces Revision Of Targets Under Medium-Term Management Plan
Tuesday, 4 Dec 2018 

Mitsubishi Chemical Holdings Corp <4188.T>::MITSUBISHI CHEMICAL HOLDINGS CORP - ANNOUNCES REVISION OF TARGETS UNDER MEDIUM-TERM MANAGEMENT PLAN.MITSUBISHI CHEMICAL HOLDINGS CORP - AIMS FOR FY2020 CORE OPERATING INCOME OF 410 BILLION YEN FROM ORIGINAL TARGET OF 380 BILLION YEN.MITSUBISHI CHEMICAL - AIMS FOR FY2020 NET INCOME OF 220 BILLION YEN VERSUS ORIGINAL TARGET OF 180 BILLION YEN.MITSUBISHI CHEMICAL - AIMS FOR FY2020 ROE OF 13 PERCENT VERSUS ORIGINAL TARGET OF 12 PERCENT.  Full Article

Mitsubishi Chemical Holdings & Niantic Invest In Digilens For Holographic AR Displays
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Digilens::MITSUBISHI CHEMICAL HOLDINGS CORPORATION AND NIANTIC, INC. INVEST IN DIGILENS FOR HOLOGRAPHIC AR DISPLAYS.  Full Article

Mitsubishi Chemical Holdings unit says acquisition of US co Praxair's European businesses
Thursday, 5 Jul 2018 

July 5 (Reuters) - Mitsubishi Chemical Holdings Corp <4188.T>:Says its unit Taiyo Nippon Sanso Corp <<<4091.T>>> to buy US company Praxair, Inc.'s European businesses, effective November .Acquisition price of 5 billion euros(approximately 643.8 billion yen) and advisory costs of approximately 2.7 billion yen .  Full Article

Mitsubishi Chemical Holdings lowers conversion price for 2022 due and 2024 due euro-yen denominated convertible bonds
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Mitsubishi Chemical Holdings Corp <4188.T>:Says it lowers conversion price for 2022 due euro-yen denominated convertible bonds to 1,262.2 yen from 1,276 yen.Says it lowers conversion price for 2024 due euro-yen denominated convertible bonds to 1,244.4 yen from 1,258 yen.Effective April 1.  Full Article

R&I affirms Mitsubishi Chemical's rating at "A" and says stable outlook -R&I
Wednesday, 18 Apr 2018 

April 18(Reuters) - Mitsubishi Chemical Holdings Corp <4188.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I.Rating outlook stable -R&I.  Full Article

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I
Wednesday, 18 Apr 2018 

April 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Says rating outlook stable -R&I.  Full Article

R&I affirms Taiyo Nippon Sanso's rating at "A" and says stable outlook -R&I
Wednesday, 18 Apr 2018 

April 18(Reuters) - Taiyo Nippon Sanso Corp <4091.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I.Rating outlook stable -R&I.  Full Article

Mitsubishi Chemical Holdings unit says MMA Monomer and PMMA plants start commercial operations in Saudi Arabia
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Mitsubishi Chemical Holdings Corp <4188.T>:Says co's unit Mitsubishi Chemical Corporation announced today that its MMA monomer and PMMA plants have started commercial operations in Saudi Arabia.  Full Article

Ube Industries, JSR and Mitsubishi Chemical announce start of new company for integration of ABS resin business
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - JSR Corp <4185.T>:Says it will start to set up a Tokyo-based company on April 1, for integration of ABS resin business, with UMG ABS, Ltd., which is equally owned by Ube Industries Ltd <<<4208.T>>> (50 percent) and Mitsubishi Chemical Corp (50 percent).Says the new company will be capitalized at 3 billion yen .Says it will hold 51 percent stake in the new company after transaction .  Full Article

Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .  Full Article

UPDATE 1-Japan Inc's global push drives Asia M&As, offsets China slowdown

* 2020 Olympics big draw for investment in Japan (Updates to indicate picture available)